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First, let me thank the American Society of Human
Genetics for this great honor. For the 40 years that I have
attended the ASHG meeting, I have been impressed with
the signiﬁcance of the Allan Award in honoring research
accomplishment in human genetics. This is a very impor-
tant day for me, and I greatly appreciate your recognition.
Before going further, I’d like to say that there is someone
we all miss verymuch at this meeting, VictorMcKusick. He
did so much for the ﬁeld of human genetics and for our
society. Victor meant a lot to me during my 25 years at
Johns Hopkins, both personally and professionally. His
intellect was extraordinary, but he never ﬂaunted it.
What a wonderful man he was!
Now, I’d like to tell you about my journey in human
genetics, hitting the high points and providing a few anec-
dotes and philosophical comments. I’ll also stress the role
of teamwork and interaction with colleagues in the
research process. I’ll end by discussing what has gotten
me excited in the lab presently. In doing research, I’ve tried
to work on important problems, yet ones that were solv-
able using available methods. I’ve also tried not to follow
the crowd, but in the words of Robert Frost to take ‘‘the
Haig H. Kazazian, Jr.The Americroad less traveled by, And that has made all the difference.’’
Every researcher is a gambler, but the smart gambler likes
odds that are not too long. In research, problems with odds
of success about 5 or 10:1 are good problems. If the odds
are 2:1, the problem is probably not so important. If the
odds are 100:1, the problem is too risky. I’m going to
tell you about my research course starting from globin
regulation in the thalassemias, then turning to ‘‘jumping
genes,’’ and how even though those subjects seem quite
disparate, the course followed a logical route. Because of
time constraints, I won’t speak about other projects,
namely, cystic ﬁbrosis work by Garry Cutting, schizo-
phrenia research with Ann Pulver, characterization of
hemophilia A mutations with Stelios Antonarakis, and
gene therapy of hemophilia A in the mouse and dog
models by Rita Sarkar and Denise Sabatino.
My ﬁrst research experience was at Dartmouth Medical
School in the summers of 1958 to 1960. Before starting
medical school after my junior year in 1958, I asked the
Dean whether I should work as a hospital orderly. He told
me to spend the summer doing biochemical research with
Lafayette Noda on rabbit creatine kinase. The following
two summers I worked with Lucille Smith on bacterial elec-
tron transport. However, after transferring to Hopkins for
the last 2 years of medical school, I remained unconvinced
that research was my career path. I enjoyed an elective in
child psychiatry, and decided to train in pediatrics.
As a fourth year medical student in 1962, I took an elec-
tive taught by Barton Childs in genetics. Parenthetically,
this was the only time that 8 week course was given.
Each of six students and two faculty gave a seminar on
a literature topic. I remember telling Barton in his ofﬁce
that I knew nothing about genetics, and he said, ‘‘Don’t
worry, you’ll learn.’’ My seminar was on the cytogenetic
abnormalities that were being published almost weekly at
that time, and I got hooked on human genetics. At that
time, I also got hooked on Lilli, my loving wife of many
years. After an internship in pediatrics at the University
of Minnesota, I decided to do a genetics fellowship after
only one year of residency. I wrote Barton asking him to
suggest places to train. He mentioned a few places
including Hopkins, where he had recently obtained an
NIH training grant. After reading the ground-breaking
Davidson, Nitowsky, and Childs paper1 in PNAS demon-
strating the validity of the Lyon hypothesis in humans,
I decided to train with Dr. Childs.1Department of Genetics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
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At Hopkins, Childs suggested that I study genetic varia-
tion in fruit ﬂies in Bill Young’s lab, and we were successful
in demonstrating that X chromosome dosage compensa-
tion in ﬂies does not proceed by the same X inactivation
mechanism used by mammals.2 That was the gist of my
ﬁrst paper in 1965.
After 20 months at Hopkins and with the U.S. Army
breathing down my neck, I joined the U.S. Public Health
Service at the NIH. Luckily, I found a position with Harvey
Itano largelydue toa recommendation frommyDartmouth
mentor, Lafayette Noda. Note the Japanese-American
connection. With Itano, I did research on the regulation
of globin synthesis in humans. Then Bob Cooke, Chair of
Pediatrics at Hopkins, offered me a faculty position, but
I asked Dr. Cooke to let me ﬁnish a third year of pediatric
training at Hopkins ﬁrst. During elective time in that resi-
dency year, I wrote my ﬁrst successful RO1 application on
globin gene regulation. So I had funding when I joined
the faculty in 1969.
I started working on separating the alpha and beta globin
messenger RNAs in a small operation, a technician andme.
However, I occupied the lab designated for Childs, so the
spacewas ample. I knew that in order to succeed competing
against larger, smarter labs I would need to spend most of
my time on research. My goal was to emulate the high-
quality research in the basic sciences at Hopkins.
Shortly thereafter, Mike Kaback started his Tay-Sachs
screening program in the Baltimore Jewish community.3
He suggested that if adult hemoglobin were produced in
the fetus, onemight similarly be able to do carrier screening
and prenatal diagnosis for sickle cell anemia. I was keen to
look into this, and Morley Hollenberg, an MD student
with an Oxford DPhil, quickly found hemoglobin A
synthesis in the midtrimester fetus using techniques that I
had learned atNIHwith Itano.4 Prenatal detectionofhemo-
globin A was my entree into the prenatal diagnosis ﬁeld.
In the early 1970s I continued to work on the mRNA
imbalance in the alpha- and beta-thalassemias. In 1975,
John Phillips, a former chief resident at Boston Children’s,
joined the lab. John did lovely studies of normal globin
mRNA ratios,5 but his breakthrough came through a fortu-
itous chain of events.
In early 1978, Ned Boyer, a senior faculty in McKusick’s
Division of Medical Genetics, sent Alan Scott, a postdoc,
to Alec Jeffreys’s lab in England to learn Southern blotting.
After Alan returned, Phillips suggested and I agreed that he
learn Southern blotting from Alan. Y.W. Kan had recently
found a HpaI polymorphic site 30 of the beta-globin gene,
and demonstrated its usefulness in prenatal diagnosis of
sickle cell anemia.6 Soon thereafter, Jeffreys found two
polymorphic HindIII sites in the gamma-globin genes.7
Phillips used Southern blotting to ﬁnd extended linkage
disequilibrium involving the Beta S mutation and the
HpaI and HindIII sites.8 Out of eight possibilities for the
three sites, there were only four varieties of Beta S-bearing
chromosomes. The 60% with the HpaI site lacked both
HindIII sites,whereas the 40%without theHpaI site usually106 The American Journal of Human Genetics 84, 105–114, Februarycontained one HindIII site. This setup allowed an increase
in precise prenatal detection of sickle cell anemia by linkage
analysis from 60% to 85%.8 This paper was crucial to the
thinking thatwent into our later work characterizingmuta-
tions in beta-thalassemia. In 1979, we hired Corinne
Boehmto runourmolecular diagnosis program,which con-
sisted only of prenatal diagnosis of sickle cell anemia by
linkage analysis.
In July 1980, Antonarakis entered the picture. He had
written me asking for a genetics training position. I had
no extra money to pay him, but he said he’d come without
pay. His letter languished on my desk until another
colleague, George Stamatoyannopoulos, called from Seat-
tle to push for Antonarakis. George was very persuasive,
so I hired Stelios without pay. Once he arrived, he got
$5000 from the Greek church in Baltimore. On Christmas
day 1980, at a family get-together in Detroit, I received
a call from the Armenian industrialist and family friend
I had solicited. He said he’d provide another $5000 for
Antonarakis. So Stelios was paid something.
Antonarakis used Southern blotting to ﬁnd more RFLPs
in the beta globin cluster. He found three new HincII site
polymorphisms in the epsilon and pseudo-beta regions.
Meanwhile, Kan had found a polymorphic BamHI site 30
of the beta gene.9 Then Stelios found a polymorphic AvaII
site in the beta gene itself. Parenthetically, these RFLPs
became SNPs 20 years later. In studying these polymorphic
sites in families, there emerged an interesting pattern.
There was clear linkage disequilibrium of the ﬁve sites 50
to the delta gene (only three common polymorphic
patterns were present out of a potential 32). There was
also linkage disequilibrium for the AvaII and BamHI sites
in and 30 of the beta gene (three patterns out of a predicted
four).10 However, the two regions of disequilibrium
combined together randomly, i.e., the three 50 patterns
randomly associated with the three 30 patterns. This sug-
gested thatwithin the intervening ~12 kbwas a recombina-
tion hot spot.10 Indeed, a number of recombination events
have been seen in this hot-spot region (Figure 1).
Oneday in 1981, I asked the labwhat to call the pattern of
polymorphic restriction sites on a chromosome. Corinne
Boehm suggested the term ‘‘haplotype’’ after the usage for
HLA haplotypes coined a few years earlier by Ceppelini.
‘‘Haplotype’’ in the DNA context appeared for the ﬁrst
time in January 1982.10 Later, we found a polymorphic
TaqI siteupstreamof theepsilongene thatwasnot in linkage
disequilibrium with the sites in the beta globin cluster, and
thus the region extending fromthe epsilongene to thedelta
gene constituted the ﬁrst ‘‘haplotype block’’ as analyzed by
Chakravarti.11 This was my introduction to genomic anal-
ysis to which I later returned in studies of mobile DNA.
In 1980, we used haplotypes to carry out prenatal diag-
nosis of beta-thalassemia in families with a previously
affected child.12 However, we wondered whether the
lesson of restriction-site polymorphisms and their linkage
disequilibrium with the Beta S mutation would carry
over to beta-thalassemia. By this time, three labs had13, 2009
sequenced six beta-thalassemia genes, but only two
different mutations had been found, each one three times.
Since we had few beta-thalassemia patients at Hopkins,
I called Pat Giardina, Director of the Thalassemia Clinic
at New York Hospital. She had a large patient population,
and could get blood samples on families. To do haplotype
analysis, we needed blood on trios, the patient and
both parents. Amazingly, within 1 month Giardina had
sent blood on some 30 trios which the lab quickly
haplotyped.
Around this time I contacted Stuart Orkin, a friend and
globin colleague, at Boston Children’s. Stu was interested
in sequencing beta-thalassemia genes. I thought that
perhaps different normal chromosome backgrounds were
hit by different mutations (Figure 2), and because the
beta-globin cluster was so small there had been insufﬁcient
time in generations for the mutations to move to different
haplotypes by recombination. Thus, we might have a neat
analytical way to characterize all the common mutations
causing beta-thalassemia. I suggested to Stu that I send
him speciﬁc beta-thalassemia DNAs each containing beta-
thalassemia mutations on different haplotypes. After send-
ing the ﬁrst three DNAs to Boston, I remember Stu’s call
a few weeks later. He had sequenced three beta genes of
interest, and they all had different mutations that had
Figure 1. Linkage Disequilibrium in the
b-globin Gene Cluster with a Recombination
Hot Spot
(A) The b-globin gene cluster with seven poly-
morphic restriction sites is shown: HincII
( ), HindIII ( ), AvaII ( ), HpaI ( ),
and BamHI ( ).
(B) The five 50 polymorphic sites from the
epsilon gene to the pseudo-beta gene (HincII
and HindIII) are in linkzage disequilibrium
because of 32 expected haplotypes (25), only
three are commonly present (shown in dark
blue, green, and purple). Likewise, the two
30 polymorphic sites from the beta gene and
30 to it (AvaII and BamHI) are also in linkage
disequilibrium because of four expected
haplotypes; only three are found in human
populations (shown in lighter shades of blue,
green, and purple). However, because the 50
and 30 haplotypes recombine randomly, there
is a ~12 kb region between them that is
a ‘‘recombination hot spot.’’
not been seen previously. I nearly
fainted from the excitement! We quickly
ﬁnished cloning and sequencing the
beta-thalassemia gene from nine dif-
ferent haplotypes in Mediterranean
patients, ﬁnding eight different muta-
tions.13 At this time, Orkin and I were
communicating new information daily
by phone. Stu came to Baltimore and
stayed at our home as we ﬁnished the paper. Later, we
used haplotyping followed by cloning and sequencing at
Hopkins to characterize the common beta-thalassemia
alleles in Asian Indians, Chinese, and African-American
patients.14–16 The procedure of sequencing beta-thalas-
semia genes from different haplotypes worked well. A
new allele was discovered 80% of the time. We character-
ized roughly 40 alleles that acted at a variety of steps in
gene action: transcription, RNA splicing, RNA processing,
translation, and protein stability (Figure 3). In 1984, Orkin
and I reviewed the topic.17 Beta-thalassemia was the ﬁrst
disorder caused by multiple mutations that was essentially
completely characterized at the molecular level.
However, it looked like the beta-thalassemia project
would soon become humdrum as thalassemia alleles were
characterized in different ethnic groups. Orkin and I dis-
cussed this problem at the 1983 ASHGmeeting in Newport
Beach, Virginia. He had found his future niche in transcrip-
tion factors inhematopoiesis beginningwithGATA-1. I was
still looking for mine, and it would come, but not until the
summer of 1987.
In 1985, there was another lucky occurrence. Henry Er-
lich and Norm Arnheim wanted me to consult for Cetus
in the East Bay, but I declined because the travel distance
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anything new at the company. Boy, was I wrong! In 1985,
our daughter, Sonya, decided to attend Stanford, and it
became convenient to consult at Cetus when visiting Palo
Alto. In September 1985, Lilli and I took Sonya to Stanford,
andwhile atCetusHenry andNormusheredme into a small
Figure 2. Different b-Thalassemia
Mutations on Different b-Globin Haplo-
types
The nine different 50 plus 30 combined
haplotypes have been hit by eight different
b-thalassemia mutations. The occurrence
of different mutations on the different
haplotypes is shown by different colored
lightning bolts striking the b-globin
genes. A recombination event between
haplotypes II and VIII in the recombina-
tion hotspot has led to the same mutation
on both of these haplotypes.
conference room to hear a wild idea
from Kerry Mullis. This was my intro-
duction to PCR, but although Randy
Saiki had made some progress, the
idea hadn’t proceeded very far. Over
the following year, we had little
success in the lab with PCR. But Lilli
talked me into returning to Stanford
for sophomore parent’s weekend in
October, 1986. Now upon entering
Erlich’s ofﬁce, Henry’s excitementwas
palpable. David Gelfand had cloned
Taq polymerase and the resultant
PCR bands were incredible. We then used PCR with Taq
polymerase to sequence beta-thalassemia genes directly
from leukocyte DNA to discover mutations.18 From 1982
to 1987 haplotype analysis had aided mutation discovery
in beta globin, alpha globin, phenyalanine hydroxylase,Figure 3. b-Thalassemia Mutations in Different Steps in Gene Action
b-thalassemia mutations in different steps in gene action, including transcription, RNA processing (Cap and polyadenylation), RNA
splicing, translation (initiation codon, nonsense codons, and frameshifts), and protein stability.108 The American Journal of Human Genetics 84, 105–114, February 13, 2009
and LDL receptor genes. Now it was passe´! PCR could be
used to sequence mutations directly from leukocyte DNA
in any gene whose sequence was known.
Meanwhile, in1984, to explore the full spectrumofmuta-
tions causing disease, we wanted to work on a large gene,
whose mutations unlike those in beta-globin were not
under selection, and where nearly every unrelated indi-
vidual probably had a different mutation. The ideal gene
appeared when Gitscher and colleagues at Genentech and
Wozney, Toole, and colleagues at GI cloned the factor VIII
gene that is mutated in hemophilia A.19,20 Here was the
perfect gene, very large (nearly 200 kb) and X-linked, and
Haldanehadpredicted in1938 that everyunrelated affected
male would have a differentmutation (Of course, the recur-
rent FVIII inversion found later by Gitscher made that
prediction incorrect.21). In 1984, Antonarakis and I traveled
to GI in Boston, and obtained the FVIII cDNA for mutation
analysis.
InMay 1987, Hagop Youssouﬁan, a genetics fellow,made
a key discovery.Hehadbeen characterizing FVIIImutations
in 240 hemophilia A patients by Southern blotting using
FVIII cDNA probes. Two patients had abnormal restriction
fragments, suggesting that theirmutations were insertions.
Although Hagop was leaving in July, he persuaded me to
let him clone a portion of one insertion. One Monday
morning, Hagop toldme that over theweekend he had suc-
ceeded, blotted the clonewithL1andAluprobes, and found
the insertion was part of an L1 repetitive element. Immedi-
ately, I thought this is the problem that I’ve been looking
for. L1 is an insertional mutagen that can jump into genes,
disrupt them, and cause disease. ‘‘I’m going to work on
human transposable elements.’’
At the time, I knew something about L1s. At Hopkins and
Cold Spring Harbor, I had heard Maxine Singer speak on
repeat sequences in human DNA. Moreover, Allan Scott
had joined the faculty in Pediatric Genetics, and after
cloning and sequencing a number of human L1s, he had
built an important consensus sequence for the full-length
6 kb L1.22 Scott’s consensus sequence had two open reading
frames, called ORF1 and ORF2. ORF2 contained a sequence
that when translated had similarity to the reverse transcrip-
tases of retroviruses. It was thought that these sequences
were retrotransposons, elements that could duplicate them-
selves through reverse transcriptionofanRNA intermediate.
After Youssouﬁan left, Corinne Wong took up the
project of characterizing the two L1 insertions, both of
which were 50 truncated. Meanwhile, at Singer’s suggestion
we found that the inserted L1s came from a special
subfamily of transcribed L1 elements. Shown in Figure 4
are the parents and the young man (patient JH-27) with
hemophilia A who had an L1 insertion. In Figure 5 is the
3.8 kb insertion of a 50 truncated L1 into exon 14 of JH-
27’s factor VIII gene. Note the insertion was not present
in his mother, meaning that it occurred either in her
germ cells or early in his development. We published this
paper in early 198823 and I entered the ‘‘black hole’’ of
transposable elements.The AmericIn early1988, BethDombroski joined the labas apostdoc,
and we decided to try to isolate the full-length 6 kb L1
precursor of the JH-27 insertion. Our premise was that the
precursor would have the identical sequence as the inser-
tion over the 3.8 kb of the insertion, andwould be an active
mobile element. Of course, if I had known more about
mobile elements, Iwouldhave realized that this premise de-
pended on the element acting in cis, i.e., mobilizing a copy
of itself into anewgenomic site, not in trans, i.e.,mobilizing
a copy of another element as is the case for nearly every
other transposable element. Thus, with more experience
in theﬁeld Imaynothavedone the experiment. I compared
Alan Scott’s L1 consensus sequence with the sequence of
the 3.8 kb JH-27 insertion, and found a region of 20 nucle-
otides (nts) at roughly nt. 4200 in the 6 kb L1 consensus
sequence that differed from the insertion by 3 nts. We
made an oligonucleotide (JH-27) containing the 20 nts
from the insertion sequence, and Beth carried out the blot
against DNA digested with BamHI from JH-27, his parents,
and two controls. The resultwas amazing!We thought then
that the human genome contained about 100,000 L1
sequences, but now we know that the number is greater
than 500,000. So it was a real surprise when Beth found
that instead of a smear of thousands of L1 sequences, each
individual had only a handful of bands and the patient
had a new band not present in his parents (Figure 6). This
Figure 4. Hemophilia A Patient JH-27 and His Parents at His
Bar Mitzvah
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band represented the insertion! Dombroski then obtained
a commercial lambda genomic library and cloned four
full-length L1s that hybridized with the JH-27 oligonucleo-
tide and corresponded to four of the bands on the gel. Upon
checking sequence of these four L1s, the second looked
promising.
With 5500 nts out of 6000 in hand, we had a perfect
match with the insertion sequence (Figure 7). However,
in those last 500 nts, Beth found two changes from the
JH-27 insertion. When I saw those changes on the
sequencing run, my ﬁrst thought (optimistically) was that
perhaps we had isolated an allele of the real precursor
Figure 5. L1 Insertion into Exon 14
of the Factor VIII Gene in Patient JH-27
The 3.8 kb 50 truncated insertion ends in
a poly A tract and is bracketed by short
target-site duplications. In the pedigree,
the insertion is not seen in the mother so
it occurred either in one of her germ cells
or in early embryogenesis of JH-27.
Figure 6. Hybridization of JH-27 Oligonucleotide to BamHI
Digests of DNA from JH-27, His Parents, and Two Controls
The JH-27 oligonucleotide contains three sequence changes (pink
boxes) from the L1consensus sequenceover 20nts.Note band (arrow)
inJH-27not seen in either parent, representing the L1 insertion. From
Dombroski et al., 1991.24 Reprinted with permission from AAAS.
Figure 7. Isolation of the Full-Length L1 Precursor to the
JH-27 Insertion
L1.2A has two nucleotide changes from the insertion near its 30 end
(blue ovals) and was isolated from a commercial genomic library.
However, L1.2B was isolated from a library made with the mother’s
DNA and matches the insertion sequences over its entire 3.8 kb. It
is the precursor to the insertion in JH-27 and is located on chro-
mosome 22q.
from the commercial library. To check
that possibility, Beth got genomic
sequence ﬂanking the L1, did a PCR
from the JH-27 oligonucleotide to the
ﬂank in both parents, and sequenced
the region of the two changes from
her PCR product. Voila! The parental
sequences matched the insertion—
the changes were not present in either
parent and the allele hypothesis was
probably correct. We then got blood
from the mother, and Beth cloned
the same L1 from the mother’s
genomic library. The mother’s L1 was indeed identical in
sequence over its last 3.8 kb to the insertion. It was also
the ﬁrst L1 isolated that contained two intact ORFs. It had
originated on chromosome 22 and a portion of it had been
copied and inserted into the factor VIII gene in JH-27. We
had successfully obtained the precursor from among
hundreds of thousands of L1s, and had strong evidence
for cis preference of L1 elements.110 The American Journal of Human Genetics 84, 105–114, February 13, 2009
Figure 8. L1 Insertion into an Exon of
the Dystrophin Gene Containing an Extra
500 Nucleotides 30 to the L1
This insertion disrupted expression of the
dystrophin gene, leading to Duchenne
muscular dystrophy. The extra 30 nts re-
sulted from transcription read-through of
the L1 and cleavage of the transcript only
after a downstream poly A signal. The extra
unique sequence was then used to clone
the precursor of this L1 insertion.Then Abram Gabriel, an MD postdoc at Hopkins, sug-
gested an assay for reverse transcriptase activity using
a hybrid yeast Ty1-human L1 combination. Steve Mathias,
a PhD student with Alan Scott, working with Abram and
Jef Boeke, the yeast retrotransposon expert at Hopkins,
demonstrated reverse transcriptase activity encoded by
ORF2 and the two papers were published together.24,25 All
this time, I was learning more about transposable elements
through quarterly lab meetings with Maxine Singer.
In 1993, Susan Holmes, a grad student, worked up
another interesting patient sample from the DNA diag-
nostic lab, a Duchenne patient with an L1 insertion knock-
ing out his dystrophin gene. The insertion into an exon
was unusual because it contained 500 nts of single-copy
sequence 30 to the L1 (Figure 8), which Susan used to clone
the full-length precursor on chromosome 1q.26 We know
now that 20% of L1 insertions contain extra 30 sequence
because the L1 poly A signal is weak and cleavage of the
L1 RNA often occurs only after a downstream poly A signal.
Later, John Moran showed that this mechanism, called 30
transduction, can be used by L1s to shufﬂe exons.27 This
is just one of a host of mechanisms by which L1 retrotrans-
posons drive genome evolution.28
In 1994, I moved to Penn, and Moran joined the lab as
a postdoc with one goal—to develop a tissue culture assay
for L1 retrotransposition. In 6 months, he had put a retro-
transposition cassette containing an antisense neo gene dis-
rupted by a forward intron into the 30 UTR of our insertion
precursor and had the assay working in HeLa cells beyond
our wildest dreams (Figure 9). In this assay, the only way
to get G418 resistant colonies is by a retrotransposition
event. I remember telling Moran that all those G418-resis-
tant colonies (up to1 colonyper 10–20plated cells) couldn’t
possibly represent retrotransposition events. But they did!
Donna Sassaman found that many other potentially active
L1s we isolated also retrotransposed in culture. Moran
showed that both ORFs were critical for retrotransposition,
andwehelped Jef Boeke demonstrate that L1ORF2 encodes
an endonuclease activity critical for L1 mobility.29–31
Then, Thierry Nass and Ralph DeBerardinis demon-
strated that disease-causing, full-length mouse L1s areThe Americalso active in the assay.32 John Goodier found that many
mouse L1s from three different L1 subfamilies are active,
suggesting that there are about 3000 active L1s in the
mouse.33 In 2003, Brook Brouha isolated nearly all the
potential active L1s from the reference human genome
and found that approximately half are active, indicating
that the average human diploid genome has 80–100 active
L1s, a small number compared to 3000 in the mouse.34 He
also found that only a handful of these L1s in any indi-
vidual are very active or ‘‘hot,’’ but that ‘‘hot’’ L1s account
for nearly all of the disease-causing insertions in humans.
Five out of six disease-causing, full-length L1s were
‘‘hot.’’ In 2006, Seleme showed that there is extensive indi-
vidual variation in retrotransposition capability among
human beings.35
Meanwhile, in 2002 Eric Ostertag made a number of
transgenic mouse models of L1 retrotransposition using
‘‘hot’’ human L1s containing heterologous promoters as
transgenes.36 Daria Babushok characterized a large number
of L1 insertions in transgenic mice, showing that they are
verysimilar to theendogenous insertions found inhumans.37
This has led to recent exciting work by Hiroki Kano on
the timing of retrotransposition. The ﬁeld has believed
that nearly all retrotransposition occurs in germ cells or
sufﬁciently early in the embryo so that the insertions are
heritable. After all, the human genome contains over
500,000 L1s. But just because so many insertions are
present in the genome does not mean that present-day
insertions are all heritable. Kano used endogenous human
L1s and endogenous mouse L1s both with only their own
promoters as transgenes in mice and rats. The readout for
retrotransposition was removal of an intron from the 30
UTR of the L1. He made two very surprising ﬁndings that
were observed for all transgenic lines. First, he found
L1 RNA can be carried over from the germ cell, either
sperm or ovum, into the embryo. Moreover, insertion
can occur from carried over RNA in the morula or blasto-
cyst. The second surprising ﬁnding was that most L1 retro-
transposition occurs not in germ cells even though the
L1 RNA is present, but in early embryogenesis. L1 RNA
is abundant in spermatogenic fractions, but very littlean Journal of Human Genetics 84, 105–114, February 13, 2009 111
Figure 9. Assay for Retrotransposition in Cultured Cells
(A) A retrotransposition cassette containing a backward neo gene disrupted by a forward g-globin intron is placed into the 30 UTR of an
active L1. This marked L1 is then cloned into a pCEP4 expression vector that is transfected into transformed human cells, e.g., HeLa cells.
The only way to get G418R colonies is by transcription from the L1 promoter, splicing out of the intron, reverse transcription, and inte-
gration of the now-intact neo gene.
(B) Results of retrotransposition assays for different human L1s. Each blue-stained colony represents a clone of cells with a retrotrans-
position event. The D702Y mutation affects reverse transcriptase activity of L1.2 and causes a major reduction in retrotransposition
activity. Note the variability in the retrotransposition activity of various active human L1s.L1 insertion is observed in those fractions. However, there
is considerable retrotransposition in the preimplantation
embryo even though there is much less total DNA in the
sample (H. Kano, I. Godoy, C. Courtney, M.R. Vetter, G.L.
Gerton, E.M. Ostertag, and H.H.K, unpublished data).
These results suggest a posttranscriptional block for
insertion in germ cells and the very early embryo.
Although there is abundant L1 RNA in germ cells, very
little actually retrotransposes, but this block is lifted by
the morula stage (around the 100-cell embryo). The results
suggest that we are mosaic for L1 insertions in our tissues,
and that we may contain a very large number of somatic
insertions at low frequencies per cell. Insertions in impor-
tant genes could lead to susceptibility to common diseases,
including oncogenic and neurologic conditions. We are
exploring these possibilities using new high-throughput
sequencing methods. There are still a number of unan-
swered questions in the retrotransposition ﬁeld, some of
which include:
What is the frequency of both heritable and nonherit-
able L1 retrotransposition from one generation to the
next?
What are the genetic and epigenetic factors that lead to
individual differences in retrotransposition capability?
What host factors are critical for retrotransposition?
Weknow that retrotransposition events have caused~65
single gene disorders. How extensive is their role in
common, multifactorial disease?112 The American Journal of Human Genetics 84, 105–114, FebruarAs you can tell, progress in human genetics takes an
army. I have been blessed with many outstanding fellows,
graduate students, postdocs, and research assistants over
the years at Hopkins and Penn. I have had outstanding
colleagues at these institutions and elsewhere. I thank
themall for theirmany contributions. It’s been awonderful
journey that isn’t over yet! I particularly thank Barton
Childs, mymentor for many years. He always said, ‘‘You’ve
got to burn to do research.’’ You need very high motiva-
tion! I especially thank my wife, Lilli, and children, Haig
and Sonya, for putting up with me all these years. Thanks
again to the American Society of Human Genetics for this
wonderful honor and to all of you for listening.
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